@oncoalert.bsky.social
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
@oncoalert.bsky.socialExploring New Treatment Strategies and Future Advances in Oncology
#FlorenceConsensus26 🇮🇹 Coverage by @OncoAlert 🚨
In "Tumor Evolution and Therapeutic Sequencing in HR+ HER2- Breast Cancer," Barbara Pistilli (Gustave Roussy) contrasts clinical and biological definitions of endocrine resistance
@oncoalert.bsky.socialExploring New Treatment Strategies and Future Advances in Oncology
#FlorenceOncology26 🇮🇹 Coverage by @OncoAlert 🚨
"What Have We Learned from UK Breast Radiotherapy Trials and What's Next?", Charlotte Coles (University of Cambridge) traces three decades of UK trials. START, FAST & FAST-Forward
@oncoalert.bsky.socialExploring New Treatment Strategies and Future Advances in Oncology
#FlorenceOnco26 Coverage by @OncoAlert 🚨
In "From Patients to Partners: The Power of Advocacy in Oncology," patient advocate Hilary Stobart (Independent Cancer Patients' Voice) distinguishes patient involvement, engagement
@oncoalert.bsky.socialA Great start to #FlorenceOncology26 🇮🇹 with WARMING UP: Exploring New Treatment Strategies and future Advances in Oncology!!
Hope you are here to join us in Florence Italy to experience firsthand some great presentations and discussions in #BreastCancer , #ProstateCancer , #HeanandNeckCancer & More
@oncoalert.bsky.socialAfter IO, the road in #RCC gets murky 🌫️
So our good friends the UROMIGOS (Dr. Brian Rini & Dr. Tom Powles) asked global experts to score each option, from 0 (avoid) to 3 (SOC).
Where's the consensus, and where's the split? 🔥
Dr. Laurence Albiges walks us through it 👇
@oncoalert.bsky.socialThis week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc
🔦 MATTERHORN: perioperative durvalumab + FLOT improves overall survival in resectable gastric cancer, a new standard of care
✅ FDA approval based on HER2CLIMB
@oncoalert.bsky.socialFDA NEWS🇺🇸 HER2CLIMB-05 Update in #BreastCancer
On October 7, 2026, the FDA approved tucatinib with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction therapy.
@oncoalert.bsky.social🧬 Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?
SKYSCRAPER-02C🫁 Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage #SCLC
@oncoalert.bsky.social📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow**
📅 November 11–13, 2026
📍 New York, NY 🇺🇸
💻 Hybrid Meeting — In Person + Online
🎟️ FREE REGISTRATION with code: ONCOALERT
👉 buff.ly/b5A7hsf
@oncoalert.bsky.social📣 Early Bird Registration for #IKCSNA26 Now Open
Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America
@oncoalert.bsky.socialThe OncoAlert #ESMO26 PULSE is ready 🇪🇸
As Madrid gets closer, your OncoAlert Network has gathered the faculty who will report live from ESMO and keep you up to date on the science out of Spain.
In the room or following from home, we've got you covered.
✅ Less noise
✅ No nonsense
✅ Just science
@oncoalert.bsky.socialIs perioperative immunotherapy finally changing the standard of care in resectable gastric cancer? 🧬
www.thelancet.com/journals/lan...
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma MATTERHORN
@oncoalert.bsky.socialDear Colleagues, Join @OncoAlert 🚨 LIVE in FLORENCE Italy Oct 9–10, for the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments (endorsed by ESTRO)
)
REGISTER HERE 👉 buff.ly/I8wKRpo
@oncoalert.bsky.socialDoes adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
www.thelancet.com/journals/lan...
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early NSCLC
@oncoalert.bsky.socialCould biomarkers🎯 help us better identify which patients with advanced RCC are most likely to benefit from immunotherapy?
www.annalsofoncology.org/article/S092...
KEYNOTE427
Results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab 🧪 mono in advanced RCC
@oncoalert.bsky.socialThis week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc
This week's must-reads:
🔸 Spotlight: Giredestrant + everolimus in ER+/HER2− ABC, PFS HR 0.38 in ESR1m (NEJM)
🔸 FDA: belzutifan + lenvatinib approved in ccRCC;
@oncoalert.bsky.socialGiredestrant plus Everolimus in Advanced Breast Cancer
Could targeting both ER and PI3K–AKT–mTOR pathways help overcome endocrine resistance? 👇
www.nejm.org/doi/full/10....
@oncoalert.bsky.socialWhy do some TNBC tumors respond to immunotherapy🧪 while others rapidly develop resistance?
A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
@oncoalert.bsky.social🚨 Join us at the 2026 International Symposium of Gastrointestinal Oncology (#ISGIO2026), October 2–3, 2026!
🆓 FREE registration with code: ONCOALERT
👉 Register: www.gotoper.com/courses/meet...
This multidisciplinary program covers the latest advances in GI cancer research and biomarkers
@oncoalert.bsky.socialDear GU Colleagues at #ASTRO26 ! Join us at the first LPCCC – Localised Prostate Cancer Consensus Conference, where challenging and unresolved questions in Prostate Cancerwill be discussed, debated and brought into focus. #LPCCC27
JUST NOW CALL FOR ABSTRACTS ARE OPEN
apccc.org/call-for-abs...
